Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
OF THE WORLD HEALTH ORGANIZATION CLASSIFICATION OF TUMORS OF THE HEMATOPOIETIC AND LYMPHOID TISSUES
This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …
lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage …
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
OK Weinberg, A Siddon, YF Madanat, J Gagan… - Blood …, 2022 - ashpublications.org
A subset of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) show
complex karyotype (CK), and these cases include a relatively high proportion of cases of …
complex karyotype (CK), and these cases include a relatively high proportion of cases of …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
L Malcovati, U Germing, A Kuendgen… - Journal of clinical …, 2007 - ascopubs.org
Purpose The aims of this study were to identify the most significant prognostic factors in
myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and …
myelodysplastic syndromes (MDS) taking into account both their values at clinical onset and …
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients
D Haase, U Germing, J Schanz… - Blood, The Journal …, 2007 - ashpublications.org
We have generated a large, unique database that includes morphologic, clinical,
cytogenetic, and follow-up data from 2124 patients with myelodysplastic syndromes (MDSs) …
cytogenetic, and follow-up data from 2124 patients with myelodysplastic syndromes (MDSs) …
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes
MG Della Porta, L Malcovati, E Boveri… - Journal of clinical …, 2009 - ascopubs.org
Purpose We studied bone marrow (BM) histologic abnormalities in myelodysplastic
syndromes (MDS) classified according to WHO criteria to determine their clinical correlates …
syndromes (MDS) classified according to WHO criteria to determine their clinical correlates …
[HTML][HTML] Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in …
AA van de Loosdrecht, C Alhan, MC Bene… - …, 2009 - ncbi.nlm.nih.gov
The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases
characterized by cytopenia (s), dysplasia in one or more cell lineages and increased risk of …
characterized by cytopenia (s), dysplasia in one or more cell lineages and increased risk of …
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 …
PL Greenberg, Z Sun, KB Miller… - Blood, The Journal …, 2009 - ashpublications.org
This phase 3 prospective randomized trial evaluated the efficacy and long-term safety of
erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive …
erythropoietin (EPO) with or without granulocyte colony-stimulating factor plus supportive …
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes
MG Della Porta, E Travaglino, E Boveri, M Ponzoni… - Leukemia, 2015 - nature.com
Abstract The World Health Organization classification of myelodysplastic syndromes (MDS)
is based on morphological evaluation of marrow dysplasia. We performed a systematic …
is based on morphological evaluation of marrow dysplasia. We performed a systematic …